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Abstract 
Repeated cycles of first-line chemotherapy drugs such as doxorubicin (DOX) and cisplatin (CIS) trigger 
frequent chemoresistance in recurrent urothelial bladder cancer (UBC). Nitroxoline (NTX), an antibiotic 
to treat urinary tract infections, has been recently repurposed for cancer treatment. Here we aimed to 
investigate whether NTX suppresses drug-resistant UBC and its molecular mechanism. The 
drug-resistant cell lines T24/DOX and T24/CIS were established by continual exposure of parental cell 
line T24 to DOX and CIS, respectively. T24/DOX and T24/CIS cells were resistant to DOX and CIS, 
respectively, but they were sensitive to NTX time- and dose-dependently. Overexpressions of STAT3 
and P-glycoprotein (P-gp) were identified in T24/DOX and T24/CIS, which could be reversed by NTX. 
Western blot revealed that NTX downregulated p-STAT3, c-Myc, Cyclin D1, CDK4, CDK6, Bcl-xL, 
Mcl-1, and Survivin, which were further confirmed by Stattic, a selective STAT3 inhibitor. In vivo, NTX 
exhibited the significant anti-tumor effect in T24/DOX and T24/CIS tumor-bearing mice. These results 
suggested that NTX-induced P-gp reversal, G0/G1 arrest, and apoptosis in drug-resistant UBC were 
mediated by inhibition of STAT3 signaling. Our findings repurpose NTX as a novel STAT3 inhibitor to 
induce P-gp reversal, G0/G1 arrest, and apoptosis in drug-resistant UBC. 
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Introduction 
Urothelial bladder cancer (UBC) is a malignant 
tumor originating primarily from the transitional cells 
of bladder urothelium [1]. The 2021 Cancer Statistics 
[2] reported an estimation of 83,730 new UBC cases 
and 17,200 UBC-specific deaths in America. 
Moreover, 50%-70% patients with non-muscle- 
invasive bladder cancer (NMIBC) will suffer a relapse 
following transurethral resection, while approxima-
tely 30% will progress into muscle-invasive bladder 
cancer (MIBC), mainly causing UBC-specific deaths 
[3]. Both doxorubicin (DOX/ADM/ADR) and 
cisplatin (CIS/DDP/CDDP) have been the first-line 
chemotherapy drugs effectively against UBC, but the 
high rates of DOX- and CIS- chemoresistance in 
recurrent UBC remain a major barrier to improve the 
prognosis of patients [4, 5]. It still maintains a 
challenge to explore novel effective chemotherapeutic 
agents for the treatment of drug-resistant UBC. 
Multidrug resistance (MDR), a clinical obstacle 
to the long-term success in chemotherapy, represents 
the cross-resistance of tumor cells to various 
chemotherapeutic agents with different structures 
and functions [6]. One of the main reasons for MDR 









brane glycoprotein, P-glycoprotein (P-gp). It is 
encoded by the ATP-binding cassette B1 (ABCB1) 
gene, with an alternative name as multidrug 
resistance 1 (MDR1) [7]. As a drug efflux pump, P-gp 
extrudes its substrates such as DOX out of tumor cells, 
thus resulting in a reduction of intracellular drug 
concentration [8]. P-gp has also been reported to 
reduce the tumor sensitivity to the non-P-gp 
substrates such as CIS, while inhibition of P-gp has 
the potential to increase CIS sensitivity [9, 10]. Signal 
transducer and activators of transcription 3 (STAT3) 
acts as a crucial transcription factor to regulate its 
downstream target genes, which subsequently 
involves in diverse biological processes such as cell 
proliferation, survival, and chemoresistance [11]. 
Overexpression and activation of STAT3 correlate 
with the poor prognosis of UBC [12, 13], and STAT3 
requires the phosphorylation at the residues of Tyr705 
(p-STAT3 (Y705)) and Ser727 (p-STAT3 (S727)) for its 
maximal activation [14]. The chromatin 
immunoprecipitation (ChIP) assay revealed the 
potential binding of STAT3 to MDR1 gene promoter 
region, and increasing evidence suggests that 
inhibiting STAT3 activation effectively downregulates 
the expression of P-gp [15, 16]. Based on the above 
research evidence, the development of potent 
inhibitors targeting STAT3 signaling may be a 
promising therapeutic strategy against drug-resistant 
UBC. Although multiple inhibitors targeting STAT3 
in cancer have been identified in preclinical and early 
phase clinical trials, the potential low efficacy or 
adverse effects may limit their clinical transformation 
[17]. 
Drug repurposing refers to discovering novel 
indications of the currently marketed drugs which 
have been applied to treat other diseases [18]. 
Nitroxoline (NTX), an antibiotic used clinically to 
treat urinary tract infections, has been repurposed for 
the treatment of multiple tumors such as UBC [19-21], 
pancreatic cancer [22], and glioma [23]. Several 
studies have reported its anti-tumor activity against 
UBC since Shim and coworkers firstly identified NTX 
as an antiangiogenic agent in UBC through inhibition 
of methionine aminopeptidase-2 (MetAP2) [19-21]. In 
an orthotopic mouse model, NTX was demonstrated 
to exhibit anti-UBC effect with favorable safety profile 
and pharmacokinetic properties [21]. Our previous 
study has also revealed that NTX suppresses the 
progression of UBC by reversing epithelial- 
mesenchymal transition (EMT) and enhancing 
anti-tumor immunity [20]. Prior studies have noted 
that P-gp expression is identified in 
pre-chemotherapy UBC tissue samples, which 
increases with MDR after chemotherapy [24, 25].  
However, it has not been reported whether NTX 
and its analogues suppress the growth of 
drug-resistant UBC. And the mechanism whether 
NTX inhibits STAT3 signaling and reverses P-gp 
overexpression, remains to be explored at the 
molecular level. Drug repurposing of NTX in 
drug-resistant UBC may contribute to the following 
advantages including its well-known drug properties 
(pharmacokinetics, efficacy, toxicity and drug 
interactions), developing a putative agent with fewer 
funds and shorter period [21]. Both in vitro and in 
vivo experiments were performed to investigate 
whether NTX could reverse P-gp overexpression and 
effectively inhibit the growth of drug-resistant UBC 
cell lines through STAT3 signaling regulation.  
Material and Methods 
Chemicals and antibodies  
The chemicals including DOX and CIS were 
purchased from MedChemExpress (MCE, New 
Jersey, USA). Both DOX and CIS were dissolved in 
phosphate buffered saline (PBS), followed by 
ultrasonic bath and 0.22-µm filtration. Nitroxoline 
(NTX) was provided by Jiangsu Asieris 
Pharmaceuticals in China. NTX was treated as PBS 
dissolution with 0.22-µm filtration. Stattic, a selective 
inhibitor of STAT3 activation and dimerization, was 
obtained from Tocris Bioscience (#2978, Bristol, UK), 
which was treated as dimethyl sulfoxide (DMSO) 
dissolution with a 20-mM stock solution. Primary 
antibodies against β-Actin (#4970), STAT3 (#12640), 
p-STAT3 (Y705) (#9145), p-STAT3 (S727) (#9134), 
MDR1/P-gp (#13342), c-Myc (#5605), Cyclin D1 
(#2978), CDK4 (#2906), CDK6 (#3136), Bcl-xL (#2764), 
Mcl-1 (#4572), and Survivin (#2808) were provided by 
Cell Signaling Technology (CST, USA). Anti-rabbit 
IgG (#7074) and anti-mouse IgG (#7076) were the 
corresponding secondary antibodies. 
Cell culture of drug-resistant UBC cell lines  
Human UBC cell line T24 was purchased from 
the American Type Culture Collection (ATCC, USA). 
DOX-resistant bladder cancer cell line, T24/DOX, and 
CIS-resistant bladder cancer cell line, T24/CIS, were 
established from our laboratory based on continual 
exposure of parental cell line T24 to the culture media 
with DOX and CIS, respectively [26-28]. T24, 
T24/DOX, and T24/CIS cells were incubated in 
DMEM medium containing 10% FBS, 1% 
penicillin-streptomycin (Invitrogen, USA). To 
maintain the drug-resistant characteristics, T24/DOX 
cells were cultured with 1 μM DOX while T24/CIS 
cells cultured with 10 μM CIS prior to experiment. 





Cell viability assay 
T24, T24/DOX, and T24/CIS (2 × 103 /well) in 
96-well plates were allowed to attach overnight. For 
drug sensitivity analysis, T24 and T24/DOX cells 
were treated with DOX (0, 0.1, 1, 10, 20, and 100 μM) 
for 24 h, while T24 and T24/CIS cells underwent 24 h 
treatment with CIS (0, 10, 20, 40, and 80 μM). To 
determine the effect of NTX on cell proliferation, T24, 
T24/DOX, and T24/CIS cells were exposed to NTX (0, 
2.5, 5, 10, 20, and 40 μM) for 24, 48, and 72 h. At the 
indicated time points, culture media were removed 
and the cells were washed gently with PBS. The 
prepared XTT working solution (Cell Proliferation Kit 
II, #11465015001, Sigma-Aldrich) was added to the 
cells, which were subsequently incubated for 4-24 h at 
37 ℃. Finally, the optical density (OD) levels were 
determined by the Model 680 Microplate Reader 
(Bio-Rad, USA). 
Hoechst 33342 staining 
T24, T24/DOX, and T24/CIS (2 × 105 /well) in 
6-well plates firstly underwent 24 h culture. Next, 
after 48 h treatment with 0 and 40 μM NTX, cells were 
stained at room temperature with 5 µg/ml Hoechst 
33342 (#H3570, ThermoFisher Scientific, USA) for 20 
min. The occurrence of apoptotic cells was observed 
under fluorescence microscope. 
Cell cycle distribution analysis 
T24, T24/DOX, and T24/CIS (2 × 105 /well) were 
seeded in 6-well plates. After 24 h incubation with 
NTX (0, 10, 20, or 40 µM), cells were rinsed twice with 
PBS and fixed in precooling 70% ethanol for over 18 h 
at 4℃. Subsequently, they were rinsed twice with PBS 
and stain buffer (BD Biosciences, #554656). Following 
by 15 min staining in PI/RNase buffer (BD 
Biosciences, #550825), the analysis was performed by 
MACSQuant Analyzer 10 and MACSQuantifyTM 
Software 2.6. 
Apoptosis examination 
T24, T24/DOX, and T24/CIS (1.5 × 105 /well) in 
6-well plates underwent 48 h incubation of NTX. After 
twice rinsing, they underwent 1X Annexin V binding 
buffer resuspension to obtain a density of 1 × 106 
cells/ml. In the dark, cell suspension (100 μl) 
underwent 15 min treatment with FITC Annexin V (5 
µl) and PI (5 µl) (BD Biosciences, #556547). Finally, 
apoptosis was examined by MACSQuant Analyzer 10 
and analyzed by MACSQuantifyTM Software 2.6. 
Western blot analysis 
Total protein extraction was conducted with 
M-PERTM Mammalian Protein Extraction Reagent 
(#78501, ThermoFisher Scientific, USA) and then 
quantified by Bradford protein assay. The same 
amount of protein (10 μg/well) was separated by 10% 
or 12% Mini-PROTEAN Gels and then transferred to 
0.2 µm PVDF Transfer Packs (#1704156, Bio-Rad, 
USA) on the Trans-Blot Turbo transfer system 
(#170-4155, Bio-Rad, USA). After 1.5 h bovine serum 
albumin or non-fat milk blocking, and 4°C overnight 
incubation with primary antibodies, membranes 
underwent TBST washing. At room temperature, the 
secondary antibody was diluted to treat membranes 
for 1.5 h. The ECL detection reagent (#RPN2232, GE 
Healthcare) and ChemiDoc Imaging System (Bio-Rad, 
USA) were used to visualize proteins. 
Subcutaneous xenograft models of T24/DOX 
and T24/CIS 
Male BALB/c nude mice (five-week-old) kept in 
specific pathogen-free (SPF) conditions were from 
Japan SLC, Inc. (Shizuoka, Japan). The mice 
experimentation was conducted in compliance with 
the Animal Care and Use Committee, Okayama 
University.  
T24/DOX cells (1×106) or T24/CIS cells (1×106) 
in 100 µl resuspension, mixing Matrigel (BD 
Biosciences, USA) and Hank's buffered saline solution 
(HBSS) at 1:1, were used for subcutaneous inoculation 
to mouse right flank. The mice bearing about 100 mm3 
T24/DOX tumor received two-week oral 
administration of NTX (40 mg/kg) or PBS (n = 6 per 
group) once per day. It was the same with T24/CIS 
tumor-bearing mice. Both mouse body weight and 
tumor growth were measured twice a week. Surgical 
resection, weighing, and photography of T24/DOX 
and T24/CIS tumors were conducted at the indicated 
endpoint. The formula of volume = 0.52 × length × 
width2, was applied to calculate tumor growth. T-PER 
Tissue Protein Extraction Reagent (#78510, 
ThermoFisher Scientific, USA) was used for extracting 
tumor tissue protein, which was subsequently 
analyzed by western blot. For histological 
examination, T24/DOX and T24/CIS tumors 
underwent 10% formaldehyde fixation, paraffin 
imbedding, and 4 μm section cut. Hematoxylin and 
eosin (H&E) were applied to stain the sections, 
followed by observing NTX-induced morphological 
alterations. 
Statistical analysis 
GraphPad Prism 8.3 was used to perform 
statistical analyses including half maximal inhibitory 
concentration (IC50) calculation and statistical charts 
creation. Between-group difference was assessed by 
Student's t-test or one-way analysis of variance 
(ANOVA), with data expressing as mean ± standard 
deviation (SD).  






Figure 1. T24/DOX and T24/CIS cells were resistant to DOX and CIS, respectively, but sensitive to NTX. (A) T24 and T24/DOX cells were treated with 
different concentrations of DOX (0, 0.1, 1, 10, 20, or 100 μM) for 24 h, followed by the evaluation of cell viability using XTT assay. (B) T24 and T24/CIS cells were treated with 
different concentrations of CIS (0, 10, 20, 40, or 80 μM) for 24 h, followed by the evaluation of cell viability using XTT assay. Data are expressed as the mean ± SD (n=6). *P < 
0.05 vs T24 parental cells. (C) The expression levels of STAT3 and P-gp in T24, T24/DOX, and T24/CIS cells were analyzed by western blot analysis. β-actin was used as a loading 
control. (D) T24, (E) T24/DOX, and (F) T24/CIS cells were exposed to different concentrations of NTX (0, 2.5, 5, 10, 20, and 40 μM) for 24, 48, and 72 h. The cell viability was 
determined by XTT assay. Data are shown as the mean ± SD (n=6). *P < 0.05 vs the control group. 
 
Results 
Characterization of DOX-resistant and 
CIS-resistant bladder cancer cell lines  
To confirm whether bladder cancer cell lines 
acquired DOX or CIS resistance, the viability of 
T24/DOX or T24/CIS cells was determined by XTT 
assay following the indicated treatment for 24 h. 
Although DOX dose-dependently inhibited the 
proliferation of T24/DOX cells, the sensitivity to DOX 
was lower than that of parental T24 cells (Figure 1A). 
For DOX, the IC50 value in T24 cells was 0.71 μM 
[95% confidence interval (95%CI), 0.56-0.89], while 
that in T24/DOX cells was 10.93 μM (95%CI, 
6.88-17.55), with a 15.4-fold change in IC50 (Table 1). 
Similarly, CIS dose-dependently inhibited the 
proliferation of T24/CIS cells, but the sensitivity to 
CIS was lower than that of parental T24 cells (Figure 
1B). For CIS, the IC50 value in T24 cells was 16.27 μM 
(95%CI, 13.29-19.11), while that in T24/CIS cells was 
58.04 μM (95%CI, 51.11-67.55), with a 3.6-fold change 
in IC50 (Table 1). 
 
Table 1. IC50 values* of DOX, CIS, or NTX determined in T24, 
T24/DOX and T24/CIS cells. 
 T24 T24/DOX T24/Cis 
 IC50 (μM) 95%CI IC50 (μM) 95%CI IC50 (μM) 95%CI 
DOX (24 h) 0.71 0.56-0.89 10.93 6.88-17.55 - - 
CIS (24 h) 16.27 13.29-19.11 - - 58.04 51.11-67.55 
NTX (24 h) 15.22 12.77-18.19 14.91 12.99-17.02 19.72 18.11-21.53 
NTX (48 h) 7.85 7.15-8.61 10.69 9.31-12.27 11.20 10.17-12.30 
NTX (72 h) 4.48 4.17-4.82 7.32 6.55-8.16 9.15 8.09-10.27 
*IC50 values represent the concentrations of DOX, CIS, or NTX producing 50% cell 
growth inhibition. Abbreviations: IC50, half maximal inhibitory concentration; 
95%CI: 95% confidence interval; DOX: doxorubicin; CIS: cisplatin; NTX: 
nitroxoline. 
 
We next analyzed the expressions of STAT3 and 
P-gp by western blot. In Figure 1C, the levels of 





STAT3 and P-gp were upregulated in T24/DOX and 
T24/CIS cells compared with T24 parental cells. 
NTX inhibits the proliferation of 
DOX-resistant and CIS-resistant bladder 
cancer cells 
The dose- and time-dependent viability 
inhibitions were observed in T24 parental cells 
(Figure 1D), and drug-resistant cell lines T24/DOX 
(Figure 1E), T24/CIS (Figure 1F). Moreover, for 48 h 
treatment of NTX, the IC50 values in T24/DOX (10.69 
μM) and T24/CIS (11.20 μM) were slightly higher 
than that in T24 cells (7.85 μM), but IC50 values of 
NTX were not significantly different between T24 
parental cells and drug-resistant cells (Table 1). 
NTX triggers G0/G1 phase arrest in 
DOX-resistant and CIS-resistant bladder 
cancer cells 
To examine whether NTX inhibited the cell cycle 
progression, T24, T24/DOX, and T24/CIS cells were 
treated with different concentrations of NTX for 24 h, 
followed by flow cytometric analysis (Figure 2A). As 
drug concentration increased, a higher percentage of 
cells stayed at G0/G1 phase, while a lower percentage 
of cells stayed at the phases of S and G2/M in T24, 
T24/DOX, and T24/CIS cells (Figure 2B). NTX 
negatively regulated the G0/G1-related protein 
expressions (c-Myc, Cyclin D1, CDK4, and CDK6) in 
T24/DOX and T24/CIS cells (Figure 2C). 
 
 
Figure 2. NTX triggers G0/G1 phase cell cycle arrest in T24, T24/DOX, and T24/CIS cells. (A) T24, T24/DOX, and T24/CIS cells were treated with the indicated 
concentrations of NTX (0, 10, 20, and 40 μM) for 24 h. The harvested cells were incubated with PI/RNase, followed by flow cytometric analysis of cell cycle distribution. (B) The 





proportions of cells in each phase (G0/G1, S, and G2/M) are presented in the histograms. Data are expressed as the mean ± SD from three independent experiments. *P < 0.05 
vs the control group. (C) T24/DOX and T24/CIS cells were treated with NTX (0, 10, 20, and 40 μM) for 48 h. Proteins were extracted and western blot was used to analyze 
the expressions of c-Myc, Cyclin D1, CDK4, and CDK6. β-actin was used as a loading control.  
 
Figure 3. NTX induces apoptosis of T24, T24/DOX, and T24/CIS cells. (A) T24, T24/DOX, and T24/CIS cells were treated with the indicated concentrations of NTX 
(0, 10, 20, and 40 μM) for 48 h. The cells were stained with Annexin V-FITC/PI and flow cytometry was used to analyze the apoptotic rates. (B) The percentages of apoptotic 
cells are shown in the histograms. Data are expressed as the mean ± SD from three independent experiments. *P < 0.05, ***P < 0.001 vs the control group. (C) The indicated 
concentrations of NTX (0 and 40 μM) were used to treat T24, T24/DOX, and T24/CIS cells for 48 h. Hoechst 33342 was then used to stain the cell nuclei (blue), followed by 
fluorescence microscopy. Scale bar = 100 μm. (D) T24/DOX and T24/CIS cells were treated with NTX (0, 10, 20, and 40 μM) for 48 h, followed by western blot to assess the 
expressions of Bcl-xL, Mcl-1, and Survivin. β-actin was used as a loading control.  
 
NTX promotes apoptosis of DOX-resistant 
and CIS-resistant bladder cancer cells 
T24, T24/DOX, and T24/CIS cells were treated 
with NTX for 48 h, followed by flow cytometry 
(Figure 3A). The apoptotic rates of T24 cells in NTX 
groups were (14.65±1.47)%, (38.26±7.21)%, and 
(58.35±0.43)% of the total cells, compared with only 
(5.96±0.58)% in control group (Figure 3B). As NTX 
concentration increased, the apoptotic rates of 
T24/DOX cells were (4.42±0.92)%, (16.52±0.48)%, 
(30.84±0.17)%, and (53.37±2.67)%, while the rates of 
T24/CIS cells were (6.05±0.14)%, (14.49±1.89)%, 
(53.19±3.68)%, and (62.36±2.51)%, respectively (Figure 





3B). Consistent with the apoptosis trend detected by 
flow cytometry, Hoechst staining results indicated a 
higher proportion of apoptotic T24, T24/DOX, and 
T24/CIS cells in NTX-treated groups, exhibiting such 
typical morphological changes as chromatin 
condensation and nuclear fragmentations (Figure 3C).  
Western blot analysis revealed that the levels of 
Bcl-xL, Mcl-1, and Survivin decreased following NTX 
treatment (Figure 3D). Our results indicated that NTX 
promoted the apoptosis of both DOX-resistant and 
CIS-resistant T24 cells. 
 
 
Figure 4. NTX suppresses the STAT3 signaling pathway in T24/DOX and 
T24/CIS cells. (A) Western blot was used to assess the expressions of STAT3, 
p-STAT3 (Y705), p-STAT3 (S727), and P-gp in T24, T24/DOX, and T24/CIS cells after 
they were treated with NTX (0, 10, 20, and 40 μM) for 48 h. (B) T24/DOX and 
T24/CIS cells were exposed to 10 μM NTX in the presence or absence of 4 μM 
Stattic for 24 h. Western blot was then performed to detect the expressions of 
STAT3, p-STAT3 (Y705), P-gp, Cyclin D1, and Mcl-1. 
 
NTX suppresses the STAT3 signaling and P-gp 
in T24/DOX and T24/CIS cells 
Western blot was applied to analyze whether 
NTX treatment regulated the expressions of proteins 
associated with STAT3 signaling and P-gp. Figure 4A 
illustrates that NTX significantly decreased the levels 
of STAT3, p-STAT3 (Y705), p-STAT3 (S727), and P-gp 
dose-dependently.  
To further verify whether NTX induced 
apoptosis and G0/G1 arrest through the STAT3 
signaling, T24/DOX and T24/CIS cells were 
incubated with NTX (10 μM) or Stattic (4 μM) for 24 h. 
Western blot analysis demonstrated that NTX (10 μM, 
24h or 48 h) or Stattic (4 μM, 24h) alone did not 
significantly inhibit STAT3 expression, but higher 
concentrations of NTX (20 and 40 μM) decreased the 
levels of STAT3 (Figure 4A, B). The combination of 
NTX and Stattic synergistically downregulated the 
expressions of p-STAT3 (Y705), P-gp, Cyclin D1, and 
Mcl-1 (Figure 4B). These findings suggested that NTX 
could inhibit P-gp, promote apoptosis and G0/G1 
arrest in DOX-resistant and CIS-resistant T24 cell lines 
via the STAT3 pathway.  
NTX exhibits the anti-tumor effect in 
T24/DOX and T24/CIS tumor-bearing mice 
To determine NTX-induced anti-tumor effect in 
vivo, we established the T24/DOX and T24/CIS 
tumor xenograft models, followed by oral 
administration of NTX (40 mg/kg) or PBS (vehicle 
group). The representative changes of tumors were 
shown in Figure 5A, 6A, showing a significantly 
lower tumor size in NTX group than that in control 
group. The average tumor weights were (0.272±0.031) 
g for vehicle group and (0.095±0.022) g for NTX group 
in T24/DOX model (Figure 5B), while those were 
(0.420±0.121) g for vehicle group and (0.192±0.072) g 
for NTX group in T24/CIS model (Figure 6B). Similar 
for T24/DOX and T24/CIS models, the tumors grew 
slowly in NTX group when compared with the 
vehicle group (Figure 5C, 6C). No significant 
differences were found in the mean body weights of 
T24/DOX or T24/CIS tumor-bearing mice between 
NTX group and the corresponding control group 
(Figure 5D, 6D), indicating a low toxicity of NTX in 
vivo. 
The morphological changes of H&E staining 
were shown in Figure 5E, 6E. The tumor cells in 
vehicle group were intact with deeply stained, large 
and abnormal nuclei, while those in NTX group 
presented with disappeared nuclei and tumor 
necrosis. Western blot analysis of T24/DOX and 
T24/CIS tumor tissues revealed that the expressions 
of p-STAT3 (Y705), p-STAT3 (S727), P-gp, and Mcl-1 
were reduced by NTX treatment as compared to 
vehicle group, but there was no significant difference 
in STAT3 (Figure 5F, 6F).  
Discussion 
The high rates of recurrence and progression 
require repeated cycles of chemotherapy for a 
long-term duration, and subsequently trigger 
frequent MDR in UBC, leading to poor prognosis and 
heavy economic burden [3, 5]. In this study, NTX was 
firstly discovered as a STAT3 signaling inhibitor to 
trigger G0/G1 cell cycle arrest, apoptosis, and reverse 
P-gp overexpression in drug-resistant UBC. T24/DOX 





and T24/CIS cells have been well-established for 
decades to apply for basic research on UBC drug 
resistance to DOX or CIS [26-28]. Following the 
confirmation of drug-resistant characteristics, we 
identified the overexpressions of STAT3 and P-gp in 
T24/DOX and T24/CIS cells. Moreover, we 
demonstrated by XTT assay that T24/DOX and 
T24/CIS cells were resistant to DOX and CIS, 
respectively, while both of them were sensitive to 
NTX time- and dose-dependently. 
Recent studies have reported NTX arrests glioma 
and myeloma cells at G0/G1 stage [23, 29]. Flow 
cytometric analysis also indicated NTX treatment led 
to the G0/G1 accumulation of DOX- and CIS-resistant 
T24 cells. Promoting cell cycle progression is a major 
carcinogenic mechanism of the proto-oncogene 
c-Myc, which potentially binds to Cyclin D1 promoter 
and upregulates its expression [30]. As an allosteric 
regulator, Cyclin D1 forms a complex with 
cyclin-dependent kinase 4/6 (CDK4/6), and active 
complex (Cyclin D1-CDK4/CDK6) drives cell cycle 
transition from G1 to S phase [31]. To explain the 
mechanism on NTX-induced G0/G1 arrest in 
T24/DOX and T24/CIS cells, we next demonstrated 
that NTX treatment downregulated c-Myc, Cyclin D1, 
CDK4, and CDK6. 
 
 
Figure 5. NTX exhibits the anti-tumor effect on T24/DOX in vivo. (A) T24/DOX tumors were excised from mice and photographed after two-week treatment. (B) 
The average tumor weight of NTX treatment group significantly decreased compared with that of vehicle group. (C) The growth curves of T24/DOX tumors at the indicated 





days following NTX treatment. (D) No significant difference was found in the body weight of T24/DOX tumor-bearing mice between treatment group and vehicle group. Data 
are expressed as the mean ± SD. ***P < 0.001, ns: P > 0.05, vs the vehicle group. (E) H&E staining was performed to observe the morphological alterations in T24/DOX tumors 
after NTX treatment. White scale bar = 100 μm; Black scale bar = 50 μm. (F) Proteins were extracted from T24/DOX tumors and western blot was used to detect the 
expressions of STAT3, p-STAT3 (Y705), p-STAT3 (S727), P-gp, and Mcl-1.  
 
Figure 6. NTX exhibits the anti-tumor effect on T24/CIS in vivo. (A) T24/CIS tumors were excised from mice and photographed after two-week treatment. (B) The 
average tumor weight of NTX treatment group significantly decreased compared with that of vehicle group. (C) The growth curves of T24/CIS tumors at the indicated days 
following NTX treatment. (D) No significant difference was found in the body weight of T24/CIS tumor-bearing mice between treatment group and vehicle group. Data are 
expressed as the mean ± SD. **P < 0.01, ***P < 0.001, ns: P > 0.05, vs the vehicle group. (E) H&E staining was performed to observe the morphological alterations in T24/CIS 
tumors after NTX treatment. White scale bar = 100 μm; Black scale bar = 50 μm. (F) Proteins were extracted from T24/CIS tumors and western blot was used to detect the 
expressions of STAT3, p-STAT3 (Y705), p-STAT3 (S727), P-gp, and Mcl-1.  
 
Typical cellular changes, such as chromatin 
condensation, nuclear fragmentation, and even cell 
shrinkage, often accompany with the process of 
programmed cell death, apoptosis [32]. Consistently, 
we observed these typical morphological changes in 
T24, T24/DOX, and T24/CIS cells following NTX 
treatment, which were further confirmed by flow 
cytometric analysis. Mitochondria-mediated apop-
tosis is crucially regulated by the B-cell lymphoma-2 
(Bcl-2) family members, among which the 
anti-apoptotic ones such as myeloid cell leukemia 1 
(Mcl-1), B-cell lymphoma-extra large (Bcl-xL) are 
well-validated anticancer targets [33]. As a member of 
the inhibitor of apoptosis (IAP) family, Survivin is 
overexpressed in multiple cancers, and its upregu-
lation in cancer is associated with chemoresistance 
and radioresistance [34]. The anti-apoptotic protein 
expressions of Bcl-xL, Mcl-1, and Survivin could be 





negatively regulated by NTX treatment in T24/DOX 
and T24/CIS cells. 
Increasing evidence suggests the critical role of 
STAT3 in chemoresistance, proliferation, and 
apoptosis of multiple tumor cells [11]. Previous 
studies have also reported that STAT3 overexpression 
occurs in drug-resistant UBC cell lines and associates 
with poor prognosis of UBC patients [12, 13]. There-
fore, inhibition of STAT3 signaling is a promising 
therapeutic strategy to decrease chemoresistance and 
induce apoptosis of drug-resistant UBC. Consistently, 
the expressions of STAT3 and P-gp were upregulated 
in T24/DOX and T24/CIS cells compared with T24 
parental cells. After membrane surface receptors are 
stimulated by cytokines or growth factors, STAT3 can 
be activated to signal through both canonical and 
non-canonical pathways [35]. For the canonical 
pathway, the subsequent phosphorylation of STAT3 
at Y705 residue will homodimerize or heterodimerize 
through their SH2 domains (Figure 7A). Following 
nuclear translocation, STAT3 dimers can bind to 
promoter elements of target genes including the 
MDR1 gene, the cell cycle regulatory genes such as 
c-Myc, Cyclin D1, and the anti-apoptotic genes such 
as Survivin, Mcl-1, Bcl-xL, and further modulate their 
transcription [36]. For the non-canonical pathway, the 
 
 
Figure 7. Proposed mechanism for NTX-induced P-gp reversal, G0/G1 arrest and apoptosis in drug-resistant T24 cells. The molecular structure of STAT3 is 
classic in STAT family, consisting of N-term Domain for cooperative DNA binding, Coiled-coil Domain for STAT3 recruitment to a receptor, DNA binding Domain, Linker 
Domain, SH2 Domain for STAT3 dimerization, and Transactivation Domain for transcription activation. (B) STAT3 can be activated to signal through both canonical and 
non-canonical pathways. For the canonical pathway, NTX inhibits STAT3 phosphorylation at Y705 residue and then decreases the translocation of STAT3 dimers to the nucleus 
in T24/DOX and T24/CIS cells. The subsequent downregulation of target genes including MDR1 gene, the cell cycle regulatory genes such as c-Myc, Cyclin D1, and the 
anti-apoptotic genes such as Survivin, Mcl-1, Bcl-xL, will reverse P-gp, trigger G0/G1 arrest, and induce apoptosis, respectively. For the non-canonical pathway, 
NTX-downregulated STAT3 phosphorylation at S727 residue reduces the translocation of p-STAT3 (S727) to the mitochondria and finally induces cell apoptosis by the 
increased generation of reactive oxygen species (ROS). 





phosphorylation of STAT3 at S727 residue is required 
for maximal STAT3 activation [14]. The subsequent 
translocation of p-STAT3 (S727) to the mitochondria 
promotes tumor cell proliferation by reducing the 
production of reactive oxygen species (ROS), a 
mediator of cell apoptosis [37]. In this study, NTX was 
identified as a potent STAT3 inhibitor to 
downregulate the expressions of STAT3, p-STAT3 
(Y705), and p-STAT3 (S727) in T24/DOX and T24/CIS 
cells. The molecular-level explanation for NTX 
causing P-gp reversal, G0/G1 arrest, and apoptosis in 
T24/DOX and T24/CIS cells, is presented in Figure 
7B. NTX treatment downregulated the expressions of 
STAT3 and p-STAT3 (Y705), which subsequently 
decreased the translocation of STAT3 dimers into the 
nucleus. Then, the downstream targets, including 
MDR1, c-Myc, Cyclin D1, Survivin, Mcl-1, and Bcl-xL, 
were downregulated, which could reverse MDR, 
trigger G0/G1 arrest, and induce apoptosis, 
respectively. Moreover, the downregulated p-STAT3 
(S727) could promote ROS generation, which further 
mediated the apoptosis of T24/DOX and T24/CIS 
cells. According to the recent reports, there is still a 
huge controversy on whether p-STAT3 (S727) 
regulates p-STAT3 (Y705) negatively or positively 
[38-40], which needs further experimental 
confirmation. NTX and Stattic, a selective inhibitor of 
STAT3 activation, dimerization, and nuclear 
translocation [41], synergistically decreased p-STAT3 
(Y705), P-gp, and the anti-apoptotic member Mcl-1, 
which further verified NTX-mediated STAT3 
inhibition in drug-resistant UBC.  
The two-week NTX treatment (40 mg/kg/day) 
also significantly in vivo inhibited T24/DOX and 
T24/CIS tumor growth. The dosage was selected 
based on the recommended dose for urinary tract 
infections [42], the guide for dose conversion between 
animals and human [43], and animal experiments in 
previous studies [20, 21]. The mean body weights of 
T24/DOX or T24/CIS tumor-bearing mice exhibited 
no between-group difference, which also indicated its 
favorable safety profile. Interestingly, by H&E 
staining, we also observed the disappeared nuclei and 
tumor necrosis in NTX group. 
To our knowledge, this is the first report to 
discover NTX as a STAT3 inhibitor for drug-resistant 
UBC therapy. However, it should be noted that single 
agent therapy for UBC potentially leads to 
chemotherapy failure with limited therapeutic 
efficacy and drug resistance [44]. It remains to be 
investigated whether NTX or its analogues combined 
with DOX or CIS can enhance the anti-tumor effect, 
promote the extrusion of drugs into extracellular 
space by drug efflux pumps, and even delay the 
development of drug resistance in UBC without 
significantly increasing toxicity. We also noticed that 
previous clinical trials focused on the therapeutic 
effect of NTX (APL-1202) on NMIBC, while a 
multicenter study (NCT04813107, Phase I/II) on the 
combination of NTX with tislelizumab, a monoclonal 
antibody against programmed cell death protein 1 
(PD-1) [45] will be started to assess their efficacy and 
safety in cisplatin-ineligible MIBC patients. Our 
previous work found that NTX decreases the levels of 
myeloid-derived suppressor cells (MDSCs) in 
UBC-bearing murine model [20]. Interestingly, 
Takeyama et al. recently reported the elevated MDSCs 
infiltration in CIS-resistant UBC microenvironment 
[46]. Further studies are expected to verify the 
combined efficacy of NTX and PD-1 antibody, and 
whether NTX could potently inhibit drug-resistant 
UBC through targeting MDSCs.  
Conclusions 
Here we reported that NTX as a STAT3 inhibitor 
exhibits the significant efficacy against drug-resistant 
UBC. Our observations demonstrated that NTX 
induces P-gp reversal, G0/G1 arrest, and apoptosis in 
drug-resistant UBC via suppression of the STAT3 
signaling pathway. Our findings could provide a 
molecular-level basis in repurposing NTX with 
clinical implications against drug-resistant UBC by 
targeting STAT3 signaling.  
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